Publications by authors named "Paul D Abel"

Claim this Profile
C
Cardiovascular toxicities of systemic treatments of prostate cancer: oestrogen to the rescue?
Syed Imran A Shah, Hannah C P Wilson, Paul D Abel

Nat Rev Urol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.
Duncan C Gilbert, Trinh Duong, Howard G Kynaston, Abdulla A Alhasso, Fay H Cafferty, Paul D Abel

BJU Int· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.
Ruth E Langley, Howard G Kynaston, Abdulla A Alhasso, Trinh Duong, Edgar M Paez, Richard L Abel, Paul D Abel

Eur Urol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeated vertebral augmentation for new vertebral compression fractures of postvertebral augmentation patients: a nationwide cohort study--how useful is the current clinical gold standard for fracture risk?
Hannah C P Wilson, Paul D Abel, S Imran A Shah

Clin Interv Aging· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture.
Hannah C P Wilson, Syed I A Shah, Paul D Abel, Patricia Price, Lesley Honeyfield, Richard L Abel

Cent European J Urol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parenteral oestrogen: effective and safer than both oral oestrogen and contemporary androgen deprivation therapy for prostate cancer?
Syed I A Shah, Paul D Abel, Trinh Duong, Pat Price, Ruth Langley

Scand J Urol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: androgen deprivation therapy: impact on quality of life and cardiovascular health.
Syed I A Shah, Fay H Cafferty, Ruth E Langley, Paul D Abel

J Sex Med· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.
Syed Imran Ali Shah, Ruth E Langley, Fay H Cafferty, Richard L Abel, Paul D Abel

BJU Int· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extending the case for oestradiol in androgen-sensitive prostate cancer - Authors' reply.
Ruth Langley, Fay H Cafferty, Paul D Abel

Lancet Oncol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).
Ruth E Langley, Fay H Cafferty, Abdulla A Alhasso, Stuart D Rosen, Subramanian Kanaga Sundaram, Paul D Abel

Lancet Oncol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of transdermal estrogen in the management of advanced prostate cancer.
Fay H Cafferty, Ruth E Langley, Paul D Abel

Urol Oncol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in pathologic outcomes after introduction of active surveillance in the UK: implication for focal therapy.
Markos Karavitakis, Hashim U Ahmed, Paul D Abel, Naomi Livni, Steven Hazell

Prostate· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reproducibility of quantitative assessment of altered hepatic hemodynamics with dynamic contrast-enhanced ultrasound.
Thomas P Gauthier, Aun Muhammad, Harpreet S Wasan, Paul D Abel, Edward L S Leen

J Ultrasound Med· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anatomically versus biologically unifocal prostate cancer: a pathological evaluation in the context of focal therapy.
Markos Karavitakis, Hashim U Ahmed, Paul D Abel, Steven Hazell, Mathias H Winkler

Ther Adv Urol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Margin status after laparoscopic radical prostatectomy and the index lesion: implications for preoperative evaluation of tumor focality in prostate cancer.
Markos Karavitakis, Hashim U Ahmed, Paul D Abel, Steven Hazell, Mathias H Winkler

J Endourol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Focal therapy for prostate cancer: opportunities and uncertainties.
Markos Karavitakis, Mathias H Winkler, Paul D Abel, Steven Hazell, Hashim U Ahmed

Discov Med· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. M. R. Smith, R. A. Morton, K. G. Barnette, P. R. Sieber, S. B. Malkowicz, D. Rodriguez, M. L. Hancock and M. S. Steiner. J Urol 2010;184:1316-1321.
Ruth E Langley, Fay H Cafferty, Philip A Pollock, Patricia Price, Paul D Abel

J Urol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: Claude C. Schulman, Jacques Irani, Juan Morote, et al. Androgen-deprivation therapy in prostate cancer: a European expert panel review. Eur Urol suppl 2010;9:675-91.
Ruth E Langley, Patricia Price, Paul D Abel

Eur Urol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor focality in prostate cancer: implications for focal therapy.
Markos Karavitakis, Hashim U Ahmed, Paul D Abel, Steven Hazell, Mathias H Winkler

Nat Rev Clin Oncol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: an increasing but under-recognised problem.
Ruth Langley, Pat Price, Philip Pollock, Paul D Abel

BJU Int· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival of patients with bladder cancer from a UK hospital: a 10-year follow-up study.
Vincent J Low, Duolao Wang, Paul D Abel

BJU Int· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long term androgen deprivation therapy in prostate cancer.
Jeremy L Ockrim, Paul D Abel

BMJ· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer.
Ruth E Langley, Ian F Godsland, Howard Kynaston, Noel W Clarke, Stuart D Rosen, Paul D Abel

BJU Int· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and development of a prototype endocavitary probe for high-intensity focused ultrasound delivery with integrated magnetic resonance imaging.
Iain P Wharton, Ian H Rivens, Gail R Ter Haar, David J Gilderdale, David J Collins, Paul D Abel

J Magn Reson Imaging· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in vascular flow after transdermal oestradiol therapy for prostate cancer: a mechanism for cardiovascular toxicity and benefit?
Jeremy L Ockrim, El-Nasir Lalani, Mo Aslam, Nigel Standfield, Paul D Abel

BJU Int· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis